Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study

Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV–HCV co-infected patients with HCV genotype 1. M...

Full description

Bibliographic Details
Main Authors: M. Laguno, M.A. Von Wichmann, E. Van den Eynde, J. Navarro, C. Cifuentes, J. Murillas, S. Veloso, M. Martínez-Rebollar, J.M. Guardiola, A. Jou, J.L. Gómez-Sirvent, M. Cervantes, J.A. Pineda, S. López-Calvo, A. Carrero, M.L. Montes, E. Deig, A. Tapiz, J.D. Ruiz-Mesa, A. Cruceta, E. de Lazzari, J. Mallolas
Format: Article
Language:English
Published: Elsevier 2016-12-01
Series:International Journal of Infectious Diseases
Subjects:
PEG-IFN/RBV + BOC therapy
HIV–HCV experienced patients
HCV genotype 1
Re-treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971216312127

Internet

http://www.sciencedirect.com/science/article/pii/S1201971216312127

Similar Items